Why Eli Lilly Stock Gained 39.2% In 2025

Shares of Eli Lilly (NYSE: LLY) jumped 39.2% in 2025, according to data from S&P Global Market Intelligence. The drugmaker is seeing soaring sales due to its blockbuster weight loss products called Zepbound and Mounjaro, as well as a pipeline of other drugs. It has just surpassed a market cap of $1 trillion, making it the 12th largest company in the world.Here's why Eli Lilly stock was soaring in 2025, and whether it is a buy right now at a trillion-dollar market cap. The weight-loss drug revolution is here. By countering cravings metabolically, these drugs have helped curb the troubling trend of obesity in the United States, a pandemic that has been raging for decades. Obesity rates have peaked in the country since 2022 and have fallen ever since.Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool